Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, December 3, 2010 - Adenovirus

Submission Type: BLA    Submission ID: 125296/0    Office: OVRR
Adenovirus Vaccine Live Oral Type 4 and Type 7
Applicant: Teva Women's Health, Inc.
Telecon Date/Time: 03-Dec-2010 03:20 PM        Initiated by FDA? Yes
Telephone Number:
Communication Category: Information Request
Telecon Summary:
Questions for CBER/Teva telecon to be held Monday December 6, 2010 3pm.
FDA Participants: Helen Gemignani
Non-FDA Participants: Valerie Mulligan
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:

Below are the questions and items for discussion for our Monday December 6, 2010, 3:00 pm teleconference.

1)  Your definition of seroconversion is as follows: the development of ADV (4 or 7) neutralizing antibodies at week 4 (Day 26) after study vaccine that was at least a fourfold increase in titer from baseline (visit 0) in a subject whose baseline ADV (4 or 7) titer was <1:4.  Based on the data we have received from you, it appears that you have assigned a value of 1:2 for all titers less than 1:4, thereby making the lowest seroconversion value 1:8.  Please confirm that this is the case or, if it is not, please describe the actual approach you have taken to define seroconversion.

2)  Based upon the ADV-4 clinical and immunogenicity results, have you identified a specific antibody level that is protective against ADV-4 disease, and, by extrapolation, could be considered protective against ADV-7?

3)  Please clarify the definitions used to describe the different cohorts analyzed in your submission, particularly the Initial Safety Cohort and the ITT Cohort.  The Initial safety Cohort is described as 780 individuals where were randomized in a 3:1 ratio to receive vaccine or placebo, respectively, all from Lot 1 (therefore were not included in the lot-to-lot consistency analysis), and who recorded post-vaccination symptoms on a 2-week daily diary (p.43 of Clinical Report).  The ITT Cohort is defined as “subjects enrolled subsequent to the 780 subjects enrolled in the initial safety cohort” (p.43, Clinical Report).  In Table 6, p.41 of the Clinical Report, the table heading reads “ITT/Safety Cohort,” noting that, for this descriptive table, these cohorts had been merged.  Subsequent tables, however, only mention “ITT Cohort” yet seem to reflect this merged ITT/Initial Safety Cohort.  Please confirm that, in fact, the tables occurring subsequent to Table 9 which are labeled “ITT Cohort” in fact reflect a merged ITT and Safety Cohort. If this is not the case, please clarify who, precisely, is included under the rubric of “ITT Cohort” in these tables.

4)  Please separate the adverse events (AEs) listed in Tables 29 and 30 of your clinical report into tables of solicited AEs and unsolicited AEs.  Similarly, in the revised Package Insert, while Table 2 represents a table of solicited AEs reported by ≥5% of subjects, Table 1 appears to include both solicited and unsolicited AEs.  Please separate out the solicited AEs from Table 1 and revise the table accordingly.

5)  Please refer to your August 24, 2006 submission to your IND (b)(4). Please submit this assay validation report to the BLA.

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English